A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma

Launched by NORTHWESTERN UNIVERSITY · Oct 29, 2013

Keywords

ClinConnect Summary

This clinical trial is exploring the safety and effectiveness of two types of chemical peels—Glycolic Acid and Salicylic Acid—for treating melasma, a condition that causes dark patches on the skin, typically on the face. The study is currently active but not recruiting new participants. It is designed for adults aged 18 years and older who have noticeable patches of melasma on both sides of their face and are generally in good health. Participants will need to agree not to use other melasma treatments during the study.

If eligible, participants can expect to receive one of the two types of peels and will be monitored for how well it works and any side effects. It's important to note that individuals who are pregnant, breastfeeding, or have certain medical conditions or recent treatments may not qualify for this study. This research aims to better understand which peel might be more effective in treating melasma and how safe these treatments are for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects aged 18 years or older
• • 2. Subjects with at least a 2 x 2 cm patch of melasma on each side of the face (forehead or cheek)
• • 3. Subjects in general good health
• • 4. Subjects must be willing and able to understand and provide informed consent for the use of their tissue and communicate with the investigator
• • 5. Subjects must be willing to not apply other treatment options for melasma during the course of the study
• Exclusion Criteria:
• • 1. Subjects under 18 years of age
• • 2. Subjects who are pregnant and/or lactating
• • 3. Subjects who are unable to understand the protocol or to give informed consent
• • 4. Subjects diagnosed with mental illness
• • 5. Subjects who have concurrent active uncontrolled disease to facial area (i.e uncontrolled acne)
• • 6. Subjects who have had a chemical peel in the past 3 months
• • 7. Subjects who have used a prescribed retinoid in the past 3 months
• • 8. Subjects with a bleeding disorder
• • 9. Subjects with a history of abnormal wound healing
• • 10. Subjects with a history of abnormal scarring